June 10, 2013 / 10:46 AM / 6 years ago

FDA rejects Aveo kidney cancer drug, asks for additional trial

June 10 (Reuters) - Aveo Oncology said the U.S. Food and Drug Administration denied approval for its experimental kidney cancer drug citing inconsistent trial results and asked for an additional study.

In a complete response letter to the company, the health regulator said inconsistent survival data from the drug tivozanib’s trials made the results “uninterpretable and inconclusive.”

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below